September 24,2013 | By Márcio Barra

Kadcyla (ado-trastuzumab emtansine, or T-DM1), from Roche/Genentech, was approved on the September 2013 meeting of the EMA’s Committee for Medicinal Products for Human Use. This is the drug’s third approval in a major territory, following the US FDA’s approval back in February and in Japan for the treatment of HER2+ positive inoperable or recurrent breast cancer.
Kadcyla is a therapy for patients with HER2-positive, late-stage (metastatic) breast cancer, consisting of the antibody trastuzumab, connected to a drug called DM1, from ImmunoGen. The medicine, which comes in two dosage forms, 100 mg and 160 mg, was approved for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and chemotherapy, separately or in combination.
HER2 is a protein encoded by ERBB2, a proto-oncogene located in chromosome 17. Over-expression of this proto-oncogene occurs in roughly 30% of breast cancers, and…
View original post 203 more words
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....

has this drug been approved in South Africa?
LikeLike
Has Kadkyla been approved in South Africa as I am presently on Herceptin and Xeloda. Fought BCA for 11yrs now
LikeLike